AIMS/HYPOTHESIS: There is limited evidence on how multifactorial treatment improves outcomes of diabetes when initiated in the lead time between detection by screening and diagnosis in routine clinical practice. Cardiac autonomic neuropathy (CAN) in people with diabetes indicates widespread damage to the autonomic nervous system, which may severely affect health and quality of life. We examined effects of early detection and subsequent intensive treatment of type 2 diabetes in primary care on the prevalence of CAN at the 6-year follow-up examination in a pragmatic cluster-randomised parallel group trial. METHODS:One hundred and ninety general practices were randomised to deliver either intensive multifactorial treatment (IT) or routine care (RC) as recommended by national guidelines to patients with type 2 diabetes, identified through a stepwise screening programme in the primary care setting. 1533 people (IT, n = 910; RC, n = 623) were identified and included. At the 6-year follow-up examination, measures of CAN were applied in an unselected subsample of 777 participants using heart rate variability analysis and standard tests of CAN. RESULTS: At the 6-year follow-up examination, the prevalence of early CAN was 15.1% in the RC group and 15.5% in the IT group, while manifest CAN was present in 7.1% and 7.3%, respectively. We found no statistically significant effect of intensive treatment on the prevalence of CAN compared with routine care. CONCLUSIONS/ INTERPRETATION: In the Danish arm of the ADDITION Study, signs of CAN were highly prevalent 6 years after a screening-based diagnosis of type 2 diabetes. Intensive multifactorial treatment did not significantly affect the prevalence of CAN compared with routine care. However, at follow-up the level of medication was also high in the RC group.
RCT Entities:
AIMS/HYPOTHESIS: There is limited evidence on how multifactorial treatment improves outcomes of diabetes when initiated in the lead time between detection by screening and diagnosis in routine clinical practice. Cardiac autonomic neuropathy (CAN) in people with diabetes indicates widespread damage to the autonomic nervous system, which may severely affect health and quality of life. We examined effects of early detection and subsequent intensive treatment of type 2 diabetes in primary care on the prevalence of CAN at the 6-year follow-up examination in a pragmatic cluster-randomised parallel group trial. METHODS: One hundred and ninety general practices were randomised to deliver either intensive multifactorial treatment (IT) or routine care (RC) as recommended by national guidelines to patients with type 2 diabetes, identified through a stepwise screening programme in the primary care setting. 1533 people (IT, n = 910; RC, n = 623) were identified and included. At the 6-year follow-up examination, measures of CAN were applied in an unselected subsample of 777 participants using heart rate variability analysis and standard tests of CAN. RESULTS: At the 6-year follow-up examination, the prevalence of early CAN was 15.1% in the RC group and 15.5% in the IT group, while manifest CAN was present in 7.1% and 7.3%, respectively. We found no statistically significant effect of intensive treatment on the prevalence of CAN compared with routine care. CONCLUSIONS/ INTERPRETATION: In the Danish arm of the ADDITION Study, signs of CAN were highly prevalent 6 years after a screening-based diagnosis of type 2 diabetes. Intensive multifactorial treatment did not significantly affect the prevalence of CAN compared with routine care. However, at follow-up the level of medication was also high in the RC group.
Authors: Andrew J M Boulton; Arthur I Vinik; Joseph C Arezzo; Vera Bril; Eva L Feldman; Roy Freeman; Rayaz A Malik; Raelene E Maser; Jay M Sosenko; Dan Ziegler Journal: Diabetes Care Date: 2005-04 Impact factor: 19.112
Authors: V Spallone; F Bellavere; L Scionti; S Maule; R Quadri; G Bax; P Melga; G L Viviani; K Esposito; R Morganti; P Cortelli Journal: Nutr Metab Cardiovasc Dis Date: 2011-01 Impact factor: 4.222
Authors: Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen Journal: N Engl J Med Date: 2003-01-30 Impact factor: 91.245
Authors: Simon J Griffin; Knut Borch-Johnsen; Melanie J Davies; Kamlesh Khunti; Guy E H M Rutten; Annelli Sandbæk; Stephen J Sharp; Rebecca K Simmons; Maureen van den Donk; Nicholas J Wareham; Torsten Lauritzen Journal: Lancet Date: 2011-06-24 Impact factor: 79.321
Authors: Timothy D Wiggin; Kelli A Sullivan; Rodica Pop-Busui; Antonino Amato; Anders A F Sima; Eva L Feldman Journal: Diabetes Date: 2009-05-01 Impact factor: 9.461
Authors: A Sandbaek; S J Griffin; G Rutten; M Davies; R Stolk; K Khunti; K Borch-Johnsen; N J Wareham; T Lauritzen Journal: Diabetologia Date: 2008-04-29 Impact factor: 10.122
Authors: Jesper Fleischer; Simon Lebech Cichosz; Poul Erik Jakobsen; Knud Yderstraede; Elisabeth Gulichsen; Hans Nygaard; Ebbe Eldrup; Hans Henrik Lervang; Lise Tarnow; Niels Ejskjaer Journal: J Diabetes Sci Technol Date: 2015-01-14
Authors: Jesper Fleischer; Knud Yderstraede; Elisabeth Gulichsen; Poul Erik Jakobsen; Hans Henrik Lervang; Ebbe Eldrup; Hans Nygaard; Lise Tarnow; Niels Ejskjaer Journal: J Diabetes Sci Technol Date: 2014-03-31